Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2− Advanced Breast Cancer: A Nationwide Real-World Experience

References

• Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Female Breast Cancer Subtypes. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed August 24, 2020].
   Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju055
   PubMedGoogle Scholar
• Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D. Palbociclib (pd 0332991): targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother. 2014;15(3):407–420.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE) Managing advanced breast cancer. 2017. Available from: https://pathways.nice.org.uk/pathways/advanced-breast-cancer#path=view%3A/pathways/advanced-breast-cancer/managing-advanced-breast-cancer.xml&content=view-node%3Anodes-hrpos-and-her2neg. Accessed August 6, 2020].
   Google Scholar
• Sini V, Cinieri S, Conte P, et al. Endocrine therapy in post-menopausal women with metastatic breast cancer: from literature and guidelines to clinical practice. Crit Rev Oncol Hematol. 2016;100:57–68. doi:10.1016/j.critrevonc.2016.02.008
   PubMed Web of Science ®Google Scholar
• Glück S. Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. Clin Breast Cancer. 2017;17(2):79–90.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649. doi:10.1016/j.annonc.2020.09.010
   PubMed Web of Science ®Google Scholar
• Bayraktar S, Batoo S, Al-Hattab E, Basu S, Okuno S, Glück S. Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer. Future Oncol. 2020;16(32):2661–2672.
   PubMed Web of Science ®Google Scholar
• Piezzo M, Chiodini P, Riemma M, et al. Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int J Mol Sci. 2020;21(17):6400. doi:10.3390/ijms21176400
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised Phase 2 study. The Lancet Oncology. 2015;16(1):25–35. doi:10.1016/S1470-2045(14)71159-3
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, Phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719–729. doi:10.1007/s10549-018-05125-4
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–219. doi:10.1056/NEJMoa1505270
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Palbociclib Summary of Product Characteristics. 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Accessed May 17, 2021].
   Google Scholar
• Inotai A, Csanádi M, Harsányi A, Németh B. Drug policy in hungary. Value Health Reg Issues. 2017;13:16–22. doi:10.1016/j.vhri.2017.06.003
   PubMedGoogle Scholar
• Arpino G, Michelotti A, Truini M, et al. Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. J Cancer Res Clin Oncol. 2016;142(3):669–678.
   PubMed Web of Science ®Google Scholar
• De Placido S, Giuliano M, Schettini F, et al. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast. 2018;38:86–91.
   PubMed Web of Science ®Google Scholar
• Klonoff DC. The expanding role of real-world evidence trials in health care decision making. J Diabetes Sci Technol. 2020;14(1):174–179.
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• WHO Collaborating Centre for drug statistics methodology, Oslo, Norway. 2011. Available from: http://www.whocc.no. Accessed August 5, 2020.
   Google Scholar
• Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R. Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. Cancer Treat Rev. 2019;74:21–28.
   PubMed Web of Science ®Google Scholar
• Waller J, Mitra D, Mycock K, et al. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: the IRIS Study. J Glob Oncol. 2019;5:JGO1800239. doi:10.1200/JGO.18.00239
   PubMed Web of Science ®Google Scholar
• Taylor-Stokes G, Mitra D, Waller J, Gibson K, Milligan G, Iyer S. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: results from the IRIS study. Breast. 2019;43:22–27. doi:10.1016/j.breast.2018.10.009
   PubMed Web of Science ®Google Scholar
• Taylor-Stokes G, Zhan L, Mycock KL, Miligan G, Ghale A, Mitra D. Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in Germany: results from the IRIS Study. Ann Oncolog. 2020;31(suppl_2):S62–S82.
   Google Scholar
• Petracci F, Abuin GG, Pini A, Chacón M. RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use. Ecancermedicalscience. 2020;14:1058. doi:10.3332/ecancer.2020.1058
   PubMed Web of Science ®Google Scholar
• Pizzuti L, Giordano A, Michelotti A, et al. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience. J Cell Physiol. 2019;234(6):7708–7717.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Blum JL, Rocque GB, et al. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer [published online ahead of print, 2020 Aug 13]. Future Oncol. 2020. doi:10.2217/fon-2020-0573
   PubMed Web of Science ®Google Scholar
• Blum JL, McCune SL, Salken MA, et al. First report of real-world patient characteristics and treatment patterns from POLARIS: palbociclib in hormone receptor-positive (HR+) advanced breast cancer: a prospective, multicenter, noninterventional study. Ann Oncolog. 2018;29(suppl_8):viii90–viii121. doi:10.1093/annonc/mdy272
   Google Scholar
• Fabi A, Russillo M, Ciccarese M, et al. Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2- metastatic breast cancer patients: the PALPract study. Cancer Res. 2020;80(4 Supplement):P5-11-18. doi:10.1158/1538-7445.SABCS19-P5-11-18
   Web of Science ®Google Scholar
• Gong J, Cho M, Yu KW, Waisman J, Yuan Y, Mortimer J. A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Res Treat. 2018;168(2):381–387.
   PubMed Web of Science ®Google Scholar
• Fu MR, Axelrod D, Guth AA, et al. Comorbidities and Quality of Life among Breast Cancer Survivors: a Prospective Study. J Pers Med. 2015;5(3):229–242.
   PubMed Web of Science ®Google Scholar
• Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885–892.
   PubMed Web of Science ®Google Scholar
• Sharma N, Narayan S, Sharma R, Kapoor A, Kumar N, Nirban R. Association of comorbidities with breast cancer: an observational study. Trop J Medl Res. 2015;19:168–171.
   Google Scholar
• Ng HS, Vitry A, Koczwara B, Roder D, McBride ML. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Cancer Causes Control. 2019;30(9):931–941.
   PubMed Web of Science ®Google Scholar
• Wesley MN, Ries LA, Havlik RJ, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885–892.
   PubMed Web of Science ®Google Scholar
• Ewertz M, Land LH, Dalton SO, Cronin-Fenton D, Jensen MB. Influence of specific comorbidities on survival after early-stage breast cancer. Acta Oncol. 2018;57(1):129–134.
   PubMed Web of Science ®Google Scholar
• Braithwaite D, Moore DH, Satariano WA, et al. Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1115–1125.
   PubMed Web of Science ®Google Scholar
• Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. J Gerontol a Biol Sci Med Sci. 2015;70(8):989–995. doi:10.1093/gerona/glv013
   PubMed Web of Science ®Google Scholar
• Dagli RJ, Sharma A. Polypharmacy: a global risk factor for elderly people. J Int Oral Health. 2014;6(6):i–ii.
   Google Scholar